BioCurex Blood Test Detects 90% of Leading Cancer Killer.Business Editors/Health/Medical Writers RANCHO SANTA MARGARITA Santa Margarita ("Saint Margaret") may refer to:
BioCurex Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :BOCX) announces results for lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. detection using its proprietary Serum-RECAF(TM) blood test. The results confirm 90% sensitivity with 95% specificity*. The findings further substantiate the use of RECAF(TM) as a universal cancer marker with a potential market size of $2 billion per year for all cancers. The study included 32 lung cancer patients and 103 normal donors with statistical verification. Dr. Moro commented: "Lung cancer is a terrible disease. It kills more people than any other type of cancer and it kills in a terrible way, by asphyxiation asphyxiation /as·phyx·i·a·tion/ (as-fix?e-a´shun) suffocation; the stoppage of respiration. Asphyxiation Oxygen starvation of tissues. . It is gut wrenching to realize that even thought this is a preventable disease, the number of new cases and deaths keeps increasing each year. It is well established that early diagnosis results in better prognosis and that is why it was so important to develop a sensitive lung cancer test that catches 90% of cases with only 5% of false positives. Moreover, there is no other blood test that can detect lung cancer at the present time. The ultimate benefit to society could be enormous." These results are consistent with those obtained for other types of cancer and strengthen the concept of using Serum-RECAF(TM) as a valid test for screening the general populations for cancer. Since lung cancer, as well as many other cancers, is difficult to detect, the overall value of the RECAF technology in human and market terms is significant. Dr. Moro further stated, "It is not well understood by the general public, that we have very few methods available to tell if a person has a cancer. In fact, for most cancers, there are no existing specific tests. This is why RECAF is such a valuable technology. Even if we could only detect one type of cancer, we would have a significant discovery, but the studies demonstrate that we obtain continued excellent results in many differing types of cancers and at very high detection values. We are very excited about our potential as a biotech company." About lung cancer: Lung cancer is now the most common form of cancer diagnosed in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. and a major cause of death. Lung cancer accounts for 14% of all cancers and 28% of all cancer deaths. At present, more Americans die from lung cancer than from breast, prostate, and colorectal cancers colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. combined. Lung cancer has surpassed breast cancer as the most common type of cancer in women. Smoking costs the United States approximately $97.2 billion each year in health-care costs and lost productivity. It is directly responsible for 87 percent of lung cancer cases and causes most cases of emphysema emphysema (ĕmfĭsē`mə), pathological or physiological enlargement or overdistention of the air sacs of the lungs. A major cause of pulmonary insufficiency in chronic cigarette smokers, emphysema is a progressive disease that commonly and chronic bronchitis chronic bronchitis n. Inflammation of the bronchial mucous membrane, characterized by cough, hypersecretion of mucus, and expectoration of sputum over a long period of time and associated with increased vulnerability to bronchial infection. . About BioCurex: BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging and therapeutics. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (OTCBB:BOCX), visit our website at www.biocurex.com. Note: The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. " within the meaning given to that term in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The Company intends that such forward-looking statements be subject to the safe harbors Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results. * Sensitivity is the number of true cancers picked by the test. Specificity is the percentage of normal samples that are negative with the test. Since 100% specificity is usually unattainable in biological systems, sensitivity is measured at an accepted specificity value of 95%. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion